Department of Gastroenterology, Faculty of Medicine, Çukurova University, 01330, Adana, Turkey.
Mol Cell Biochem. 2011 Jan;347(1-2):201-8. doi: 10.1007/s11010-010-0629-9. Epub 2010 Nov 2.
Cyclooxygenase-2 (COX-2) influences carcinogenesis through immune response suppression, apoptosis inhibition, regulation of angiogenesis and tumor cell invasion, and metastasis. It is now well established that COX-2 is overexpressed in many premalignant, malignant, and metastatic cancers, including hepatocellular carcinoma (HCC). DNA sequence variations in the COX-2 gene may lead to altered COX-2 production and/or activity, and so they cause inter-individual differences in the susceptibility to HCC. Functional coding region polymorphisms -1195A>G (rs689466), -765G>C (rs20417), and +8473T>C (rs5275) in the COX-2 gene have recently been shown to be associated with several human cancers but their association with HCC has yet to be investigated. We used hospital-based case-control study to assess the hypothesis that the functional COX-2 variation may affect individual susceptibility to the HCC. COX-2 polymorphisms were investigated in 129 confirmed subjects with HCC and 129 cancer-free control subjects matched on age, gender, smoking, and alcohol consumption using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The distribution of the COX-2 -1195A>G and +8473T>C genotypes were not significantly different between HCC cases and control. However, proportion of the COX-2 -765CC genotype which leads to a 30% reduction of the COX-2 promoter activity was significantly lower in patients with HCC (3.1%) when compared to control subjects (11.6%) (P < 0.05). Logistic regression analyses revealed that the COX-2 -765G>C variant genotype (-765CC) was associated with a significantly decreased risk of HCC compared with the -765GG wild-type homozygotes [P < 0.05, odds ratio (OR) = 0.25, 95% confidence interval (CI) = 0.08-0.79]. Our results suggest for the first time that the -765CC genotype of COX-2 -765G>C polymorphism, causing lower COX-2 gen expression, is a genetic protective factor for HCC. However, because this is the first report concerning the COX-2 -1195A>G, -765G>C, and +8473T>C polymorphisms and the risk of HCC, independent studies are needed to validate our findings.
环氧化酶-2(COX-2)通过抑制免疫反应、抑制细胞凋亡、调节血管生成和肿瘤细胞侵袭和转移来影响癌症的发生。现在已经证实,COX-2 在许多癌前病变、恶性和转移性癌症中过度表达,包括肝细胞癌(HCC)。COX-2 基因中的 DNA 序列变异可能导致 COX-2 产生和/或活性的改变,从而导致个体对 HCC 的易感性存在差异。COX-2 基因中的功能性编码区多态性 -1195A>G(rs689466)、-765G>C(rs20417)和+8473T>C(rs5275)最近已被证明与多种人类癌症有关,但它们与 HCC 的关联尚未得到研究。我们使用基于医院的病例对照研究来评估假设,即功能性 COX-2 变异可能影响个体对 HCC 的易感性。使用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析,在 129 名确诊 HCC 患者和 129 名癌症匹配的对照中研究 COX-2 多态性,这些对照按年龄、性别、吸烟和饮酒情况进行匹配。COX-2-1195A>G 和 +8473T>C 基因型在 HCC 病例和对照组之间的分布无显著差异。然而,COX-2-765CC 基因型的比例,其导致 COX-2 启动子活性降低 30%,在 HCC 患者中(3.1%)明显低于对照组(11.6%)(P<0.05)。Logistic 回归分析显示,与 COX-2-765GG 野生型纯合子相比,COX-2-765G>C 变体基因型(-765CC)与 HCC 发生的风险显著降低相关[P<0.05,比值比(OR)=0.25,95%置信区间(CI)=0.08-0.79]。我们的研究结果首次表明,COX-2-765G>C 多态性的-765CC 基因型导致 COX-2 基因表达降低,是 HCC 的遗传保护因素。然而,由于这是首次报道 COX-2-1195A>G、-765G>C 和 +8473T>C 多态性与 HCC 风险的关系,因此需要独立的研究来验证我们的发现。